Montelukast Teva (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from causing bronchoconstriction and airway inflammation. This results in improved breathing and reduced allergic symptoms.

The appropriate dose of Montelukast Teva is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing.

To request Montelukast Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients with exercise‑induced symptoms or allergic rhinitis, but it does not replace rescue bronchodilators for acute attacks.

Montelukast Teva tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children.

Montelukast Teva is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious adverse events, though rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, eosinophilic granulomatosis with polyangiitis, hepatic injury, and neuropsychiatric effects like mood changes or suicidal thoughts. Patients should seek immediate medical attention if these occur.

Montelukast Teva is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of the tablet’s excipients. It should be used with caution in patients with liver impairment and is not intended for acute asthma attacks.